NCT00504777View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Rheumatoid Arthritis

Interventions

DRUG

rituximab [MabThera/Rituxan]

1000mg iv on days 1 and 15

DRUG

Methotrexate

10-25mg/week po or parenteral

Trial Locations (10)

114

Tapei

333

Taoyuan District

402

Taichung

404

Taichung

407

Taichung

500

Changhua

807

Kaohsiung City

813

Kaohsiung City

00833

Kaohsiung City

00112

Taipei

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00504777 - A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents. | Biotech Hunter | Biotech Hunter